Promising leukemia drug falls short in kids trial
NCT ID NCT03913559
First seen Feb 05, 2026 · Last updated Jun 22, 2026 · Updated 13 times
Summary
This phase 2 trial tested inotuzumab ozogamicin (Besponsa) in children with B-cell acute lymphoblastic leukemia who had low levels of remaining cancer cells (MRD) despite treatment. The drug targets CD22, a protein on leukemia cells, and delivers a potent toxin. Only 5 children were enrolled before the study was terminated early, limiting what can be learned about its effectiveness and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Rady Children's Hospital San Diego
San Diego, California, 92123, United States
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Inotuzumab ozogamicin (Besponsa)
What this could lead to
If successful, this could offer a new option to clear remaining leukemia cells in children with high-risk B-ALL, potentially improving outcomes before or after transplant.
What could go wrong
The trial was terminated early with only 5 participants, so results are very limited. The drug carries a risk of liver damage and veno-occlusive disease, especially after transplant.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.